Welcome to our dedicated page for Cabaletta Bio news (Ticker: CABA), a resource for investors and traders seeking the latest updates and insights on Cabaletta Bio stock.
Cabaletta Bio, Inc. (Nasdaq: CABA) is a clinical-stage biotechnology company developing targeted cell therapies for autoimmune diseases, with news flow closely tied to its lead investigational CAR T cell therapy, rese-cel (resecabtagene autoleucel). The company regularly issues updates on clinical data, regulatory interactions, manufacturing progress and corporate developments that are relevant to investors and followers of autoimmune-focused biotechnology.
News about Cabaletta Bio often highlights clinical milestones within its RESET™ (REstoring SElf-Tolerance) development program. These updates include Phase 1/2 data readouts and trial expansions in indications such as myositis, systemic sclerosis, systemic lupus erythematosus, lupus nephritis, generalized myasthenia gravis and pemphigus vulgaris. Press releases have described outcomes from disease-specific cohorts, registrational cohort designs aligned with the U.S. Food and Drug Administration, and emerging data from cohorts evaluating rese-cel without preconditioning regimens.
Regulatory and manufacturing news is another key theme. Cabaletta Bio has reported on FDA designations for rese-cel, including Regenerative Medicine Advanced Therapy and Fast Track designations, as well as PRIME access from the European Medicines Agency. The company also issues announcements regarding chemistry, manufacturing and controls activities and its collaboration with Cellares to use fully automated platforms, such as the Cell Shuttle™ and Cell Q™, for clinical manufacturing and quality control testing of rese-cel.
Corporate and financial updates, including quarterly financial results, public offerings and participation in healthcare and investor conferences, are frequent components of Cabaletta Bio’s news flow. These communications provide context on the company’s cash position, operating plans and engagement with the investment community. For readers tracking CABA, the news stream offers insight into the progress of rese-cel across multiple autoimmune indications, evolving registrational strategies and the company’s preparations for potential future commercialization. Bookmarking the news feed can help users follow ongoing clinical, regulatory and corporate developments related to Cabaletta Bio and its RESET program.
Cabaletta Bio (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing curative targeted cell therapies for autoimmune diseases, has announced its participation in four major investor conferences in September 2024:
- Morgan Stanley 22nd Annual Global Healthcare Conference on September 4
- 2024 Wells Fargo Healthcare Conference on September 5
- H.C. Wainwright 26th Annual Global Investment Conference on September 11
- 2024 Cantor Fitzgerald Global Healthcare Conference on September 17
The company will participate in fireside chats at each event. Live webcasts of the presentations will be available on Cabaletta Bio's website, with replays accessible for 30 days after each event.
Cabaletta Bio reported its Q2 2024 financial results and provided a business update. Notable highlights include:
- Enrollment of nine patients as of August 5, 2024, in the RESET™ clinical development program, with 22 U.S. clinical sites now enrolling.
- Upcoming clinical data expected in 2H24 for RESET-Myositis™, RESET-SLE™, RESET-SSc™, and RESET-MG™ trials.
- An LN patient experienced a dose-limiting toxicity which resolved quickly, allowing the study to proceed without delays.
- Agreements with Lonza and Cellares to enhance manufacturing and scalability.
- Cash, cash equivalents, and short-term investments totaling $203.2 million, supporting operations into 1H 2026.
Financially, R&D expenses rose to $23.4M from $11.8M YoY, and G&A expenses increased to $6.9M from $4.1M YoY. The company also welcomed Dr. Sarah Yuan as Chief Technology Officer to advance its manufacturing strategy.
Cabaletta Bio, a clinical-stage biotech firm focusing on curative cell therapies for autoimmune diseases, announced its CEO, Steven Nichtberger, will participate in the Stifel 2024 Virtual Cell Therapy Forum. This event is scheduled for July 9, 2024, at 1:00 p.m. ET. Interested parties can access a live webcast and replay of the fireside chat via the company's website. The webcast will remain available for 30 days.
Cabaletta Bio reported positive initial clinical data from its Phase 1/2 RESET-Myositis and RESET-SLE trials for its investigational therapy, CABA-201.
Key findings include no serious adverse events, no CRS or ICANS, and no infections in either of the first two patients. The therapy showed the expected CAR T cell expansion and contraction with complete B cell depletion by day 15 post-infusion.
Both patients showed improvement in disease measures and were able to discontinue all maintenance therapies, except for a planned steroid taper in one case. The trials indicate a potential immune system reset, with immature, naïve B cell repopulation observed at week 8 in one patient.
The company continues to enroll patients and expects to report more data in the second half of the year. A conference call and webcast are scheduled for June 14, 2024, at 8:00 a.m. ET to discuss these findings.
Cabaletta Bio, a clinical-stage biotech firm specializing in curative targeted cell therapies for autoimmune diseases, announced its CEO, Steven Nichtberger, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024. The event will be held at 11:00 a.m. ET in New York, NY. A live webcast of the presentation will be accessible on Cabaletta Bio's website, with replays available for 30 days.
Cabaletta Bio (Nasdaq: CABA) announced its Q1 2024 financial results and provided business updates. Key highlights include the absence of CRS or ICANS in the initial patients treated in the RESET-Myositis and RESET-SLE trials, with clinical data expected at the EULAR 2024 Congress. The company is expanding the CABA-201 trial to dermatology with the RESET-PV sub-study and exploring apheresis-free manufacturing methods. Financially, Cabaletta's R&D expenses rose to $22 million, and G&A expenses increased to $6.1 million. The company holds $223.8 million in cash and investments, projected to fund operations into 2026.
Cabaletta Bio, a clinical-stage biotechnology company, will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ. The event is scheduled for May 20, 2024, in New York, NY. The company focuses on developing curative targeted cell therapies for patients with autoimmune diseases.
Summary not available.
Summary not available.
Summary not available.